October - 2018

MECFA Blog

Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Pres

Pre-clinical findings show RPL554 stimulates rare class III and IV CFTR mutants Phase 2a results demonstrate RPL554 has favorable...

Proteostasis Therapeutics' Double and Triple-Combo CF Drugs Possible Threat to Vertex Dominance

Boston-based Proteostasis Therapeutics announced positive preliminary data from its ongoing Phase I clinical trial of PTI-808 and PTI-801...

FDA Approves AzurRx Biopharma Request to Test MS1819-SD in CF Patients with EPI

AzurRx BioPharma is planning a multi-center Phase 2 trial to be conducted in the United States and Europe to evaluate its lead candidate...

Scientists Reveal New Cystic Fibrosis Treatments Work Best in Inflamed Airways

New UNC School of Medicine research led by Martina Gentzsch, PhD, and Carla Ribeiro, PhD, suggests that cystic fibrosis drugs used to...

Corbus Awarded US Patent Covering Lenabasum as Potential CF and Fibrotic Disease Treatment

Corbus Pharmaceuticals has received a patent from the U.S. Patent and Trademark Office covering all compositions that comprise lenabasum...

MS1819-SD Shows Positive Results for Exocrine Pancreatic Insufficiency in Phase 2a Trial

AzurRx BioPharma, in partnership with Mayoly Spindler, announced that a recent Phase 2a clinical trial testing MS1819-SD as a potential...

Decibel Obtains Exclusive License for ORC-13661 for Prevention of Antibiotic-related Ototoxicity

Decibel Therapeutics received worldwide, exclusive rights to develop and commercialize ORC-13661, Oricula Therapeutics’ investigational...

3rd Middle East Cystic Fibrosis Conference

New Approach Against Antibiotic-resistant Bacteria in CF Patients Shows Promise in Phase 1 Trial

Researchers may have found a new way of treating antibiotic-resistant bacterial infections, specifically Pseudomonas aeruginosa, in the...

Sound Pharmaceuticals to present initial data on the STOP Ototoxicity Study at Cystic Fibrosis Confe

Sound Pharmaceuticals (SPI) is pleased to announce that its recent submission to the upcoming North American Cystic Fibrosis Conference...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p